A volume in the Handbook of Clinical Neurology series on Parkinsons Disease and related disorders. Note that this is Part II of a two volume set on Parkinsons Disease by Koller and Melamed.
30. Physical therapy in Parkinsons disease Jean-Michel Gracies, Winona Tse, Mara Lugassy and Judith Frank (New York, NY, USA) 31. Neuroprotection in Parkinsons disease: clinical trials Fabrizio Stocchi (Rome, Italy) 32. Levodopa Thomas D. Hälbig and William C. Koller (New York, NY and Chapel Hill, NC, USA) 33. Dopamine agonists Olivier Rascol, Tarik Slaoui, Wafa Regragui, Fabiene Ory-magne, Christine Brefel-Courbon and Jean-Louis Montastruc (Toulouse, France) 34. Monoamine oxidase A and B inhibitors in Parkinsons disease Moussa B. H. Youdim and Peter F. Riederer (Haifa, Israel and Würzburg, Germany) 35. Anticholinergic medications Yaroslau Compta and Eduardo Tolosa (Barcelona, Spain) 36. Antiglutamatergic drugs in the treatment of Parkinsons disease Maria Graciela Cersósimo and Federico Eduardo Micheli (Buenos Aires, Argentina) 37. Investigational drugs Carlo Colosimo and Giovanni Fabbrini (Rome, Italy) 38. The importance of patients groups and collaboration Mary Baker and Jill Rasmussen (Sevenoaks and Redhill, UK)
Section 6 Complications of therapy
39. Motor and non-motor fluctuations Susan H. Fox and Anthony E. Lang (Toronto, Canada) 40. Levodopa-induced dyskinesias in Parkinsons disease Jose A. Obeso, Marcelo Merello, Maria C. Rodríguez-Oroz, Concepció Marin, Jorge Guridi, Lazaro Alvarez (Buenos Aires, Argentina, Pamplona and Barcelona, Spain and La Habana, Cuba) 41. Treatment induced mental changes in Parkinsons disease Kelvin L. Chou and Joseph H. Friedman (Warwick, RI, USA)
Section 7 Surgical treatment
42. Ablative surgery for the treatment of Parkinsons disease Frederick A. Lenz (Baltimore, MD, USA) 43. Deep brain stimulation J. Volkmann and G. Deuschl (Kiel, Germany) 44. Transplantation Curt R. Freed (TBC) (Denver, CO, USA) 45. Gene therapy approaches for the treatment of Parkinsons disease Biplob Dass and Jeffrey H. Kordower (Chicago, IL, USA)
Section 7 Other parkinsonian disease syndromes
46. Multiple system atrophy Ronald F. Pfeiffer (Memphis, TN, USA) 47. Progressive supranuclear palsy David J. Burn and Andrew J. Lees (Newcastle upon Tyne and London, UK) 48. Corticobasal degeneration Natividad P. Stover, Harrison C. Walker and Ray L. Watts (Birmingham, AL, USA) 49. Infectious basis to the pathogenesis of Parkinsons disease V. Dhawan and K. Ray Chaudhuri (London, UK) 50. Toxic causes of Parkinsons disease Nirit Lev, Eldad Melamed and Daniel Offen (Petah-Tikva and Tel-Aviv, Israel) 51. Drug induced parkinsonism Federico Micheli and María Graciela Cersosimo (Buenos Aires, Argentina) 52. Vascular parkinsonism Yacov Balash and Amos D. Korczyn (Tel-Aviv and Ramat-Aviv, Israel) 53. Old age and Parkinsons disease Alex Rajput and Ali H. Rajput (Saskatoon, Canada) 54. Other degenerative processes J. Carsten Möller and Wolfgang H. Oertel (Marburg, Germany) 55. Hydrocephalus and structural lesions John G.L. Morris, Brian Owler, Mariese A. Hely and Victor S.C. Fung (Sydney, Australia) 56. Calcification of the basal ganglia Jennifer S. Hui and Mark F. Lew (Los Angeles, CA, USA) 57. Trauma and Parkinsons disease Oscar S. Gershanik (Buenos Aires, Argentina) 58. Psychogenic parkinsonism Vasiliki Koukouni and Kailash P. Bhatia (London, USA) 59. Parkinsonism and dystonia Ruth H. Walker (new York, NY, USA) 60. Dementia with Lewy bodies Ian McKeith (Newcastle upon Tyne, UK) 61. Myoclonus and parkinsonism Daniel D. Truong and Roongroj Bhidayasiri (Los Angeles, CA, USA and Bangkok, Thailand)